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yliu@shmu.edu.cnAbstract A robust, selective and highly sensitive chemiluminescent (CL) platform for protein
assay was presented in this paper. This novel CL approach utilized rolling circle ampliﬁcation
(RCA) as a signal enhancement technique and the 96-well plate as the immobilization and
separation carrier. Typically, the antibody immobilized on the surface of 96-well plate was
sandwiched with the protein target and the aptamer–primer sequence. This aptamer–primer
sequence was then employed as the primer of RCA. Based on this design, a number of the
biotinylated probes and streptavidin–horseradish peroxidase (SA–HRP) were captured on the
plate, and the CL signal was ampliﬁed. In summary, our results demonstrated a robust biosensor
with a detection limit of 10 fM that is easy to be established and utilized, and devoid of light source.
Therefore, this new technique will broaden the perspective for future development of DNA-based
biosensors for the detection of other protein biomarkers related to clinical diseases, by taking
advantages of high sensitivity and selectivity.
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(C.-Y. Liu).1. Introduction
Detection of protein biomarkers in clinical samples is of great
importance for effective diagnosis and prognosis of many
diseases [1]. In general, antibody-based immunoassay systems
are versatile and powerful tools for various molecular analyses
[2]. Enzyme-linked immunosorbent assay (ELISA) is consi-
dered as a standard method to detect protein biomarkers [3].
However, the concentrations of many important biological
markers in clinical examples for cancer, infectious diseases, or
biochemical processes are too low to be detected using
conventional immunoassays [4]. Therefore, several innovative
approaches have been developed to improve the sensitivity by
combining antibody-based molecular recognition with various
Table 1 DNA sequences used in this work.
Name Sequence
Aptamer–
primer
50-TAC TCA GGG CAC TGC AAG CAA
TTG TGG TCC CAA TGG GCT GAG
Z.-J. Cao et al.160ampliﬁcation detection techniques, such as metal ion deposi-
tion [5], enzyme ampliﬁcation [6], bio-barcode detection [7,8],
proximity ligation [9,10], metal nanoparticles [11] and quan-
tum dots [12].
Among them, molecular probes based on nucleic acid
platforms are emerging. One of the representative examples
is the use of aptamer for protein analysis [13–16]. Aptamers
are short synthetic nucleotide sequences (DNA or RNA) that
have been selected in in vitro selection experiments via the
systematic evolution of ligands by exponential enrichment
(SELEX) process [17]. As a novel recognition element,
aptamers possess signiﬁcant advantages including simple
synthesis, easy labeling, good stability and design ﬂexibility
[18,19]. In addition, aptamer-based assay is easy to combine
with other ampliﬁcation methods, such as gold nanoparticles,
polymerase chain reaction (PCR) and rolling circle ampliﬁca-
tion (RCA) [20–28]. For example, Csordas et al. [22] reported
a micromagnetic aptamer PCR (MAP) detection system,
which integrated high-gradient magnetic ﬁeld sample prepara-
tion in a microﬂuidic device with aptamer-based real-time
PCR readout, to achieve highly sensitive and quantitative
detection of protein targets directly from complex samples.
RCA has also been proven to enhance signals for detecting a
variety of analytes without thermal cycling. Additionally this
RCA process is of linear kinetic ampliﬁcation model and the
RCA product was a single stranded DNA sequence consisting
of tandem repeats of the complement of the circular template.
Therefore, the RCA ampliﬁcation strategy has been used to
various detection protocols, including optical diffraction [23],
ﬂuorescent [24–26] and electrochemical [27,28] ones.
Chemiluminescence (CL) is considered one of the most suited
optical detection techniques for developing miniaturized and
highly sensitive analytical devices [29]. Even though the quantum
efﬁciency of CL reactions is usually low (in the order of 0.01 or
less), the use of enzyme labels such as horseradish peroxidase
(HRP) or alkaline phosphatase (ALP), ensures signal ampliﬁca-
tion and high sensitivity [30,31]. Because of the wide dynamic
range of the CL measurements (up to 6 orders of magnitude), the
target analyte can be detected in a broad concentration range,
from femtomolar to millimolar levels, without the need of sample
dilution. Finally, the absence of an excitation light source as in
ﬂuorescence measurements makes CL detection less sensitive to
interferences attributed to sample components (the only back-
ground signal derives from the instrumental noise) and allows a
wide range of applications in different ﬁelds such as environ-
mental chemistries [32], molecular biology [33,34], pathogenic
bacteria [35], clinical diagnosis [36] and cell sensors [37], including
several research works in our group [38–41].
Herein, we present an example of the aptamer-based RCA
assay by coupling of CL detection for the ultrasensitive
protein assay. Platelet-derived growth factor B-chain
(PDGF-BB), an important protein for cell transformation
and tumor growth and progression, was selected as the model
protein.
TAT TTT TTT TGT CCG TGC TAG AAG
GAA ACA GTT AC-30
Padlock
probe
50-phosphate-TAG CAC GGA CAT ATA
TGA TGG ACC GCA GTA TGA GTA
TCT CCT ATC ACT ACT AAG TGG AAG
AAA TGT AAC TGT TTC CTT C-30
Biotinyla-
ted probe
50-biotin-GTT TCC TTC TAG CAC-302. Materials and methods
2.1. Materials and reagents
All chemicals were of analytical grade and were used as
received. The DNA-BIND 96-well plate (Costar, 6573) hadan N-oxysuccinimide surface and was obtained from Corning
Inc. (NY, USA). The PDGF-BB proteins and goat anti-
human PDGF-BB antibody were purchased from R&D
Systems (Minneapolis, MN, USA). The PDGF proteins were
reconstituted in 4 mM HCl with 0.2% BSA prior to use. Phi
29 reagent set was purchased from Epicenter (Madison, WI,
USA). Escherichia coli DNA ligase was obtained from Takara
Biotechnology Co., Ltd. (Dalian, China). Streptavidin–
horseradish peroxidase (SA–HRP) was purchased from
Sigma-Aldrich (St. Louis, MO, USA). Bovine serum albumin
(BSA) was obtained from Sino-American Biotechnology Co.
and other reagents were purchased from Sinopharm Chemical
Reagent Co., Ltd. (Shanghai, China). HRP substrate kits were
purchased from Millipore Corporation (Billerica, MA, USA).
Oligonucleotides were obtained from Invitrogen Biotechnol-
ogy Co., Ltd. (Shanghai, China), including the following
sequences (Table 1).
2.2. Buffers
All of the solutions were prepared with water from a Millipore
system (Millipore XQ, MA, USA). Binding buffer (BB) was
0.5 M Na2HPO4–NaH2PO4, pH 8.5. PBS consisted of 2.7 mM
KCl, 1 mM MgCl2, pH 7.4. PBST was PBS containing 0.05%
Tween 20. Blocking buffer was PBS containing 5% BSA.
Ligation buffer (LB) consisted of 30 mM Tris–HCl, pH 8.0,
4 mM MgCl2, 10 mM (NH4)2SO4, 1.2 mM EDTA and
0.1 mM b-NAD. RCA reaction buffer was 40 mM Tris–HCl
(pH 7.5), 50 mM KCl, 10 mM MgCl2, 5 mM (NH4)2SO4 and
4 mM DTT.
2.3. Apparatus
CL measurement was carried out using a PC-controlled
Fluoroskan Ascent FL (Thermo Electron Corporation).
2.4. Sandwich assay with RCA or without RCA
In a typical experiment, goat anti-human PDGF-BB antibody
was diluted to 0.75 mg/mL in BB and added into the wells in a
96-well plate (100 mL each well). The plate was incubated for
1 h with gentle mixing at 37 1C. Excess PDGF-BB antibody
was removed by decanting the supernatant. The plate was
washed and blocked with blocking buffer (150 mL per sample)
for 60 min at 37 1C. After decantation of blocking buffer,
series dilutions of PDGF-BB were prepared in 100 mL PBS
46.0x104
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40 min with gentle mixing at 37 1C. After washing, 100 mL of
7.5 pmol aptamer-primer complexes in PBS and 5 pmol
padlock were added into the wells, which was incubated for
60 min at 37 1C. And then the padlock probe was circularized
via ligation by 1 U of E. coli DNA ligase in LB (100 mL each
well) for 60 min at 37 1C to form the circular template for
RCA. The complex was incubated with 100 mL of 40 U phi29
DNA polymerase and 100 mM dNTPs in RCA reaction buffer
for 75 min at 37 1C. After a rinsing step, 100 mL of 7.5 pmol
biotinylated probe (at the 50 end) was applied to and
hybridized with the resulted RCA products, which then
captured the SA–HRP (1:7500 dilution, 100 mL per well).
Finally, the plate was washed three times with 150 mL of
PBST. The CL signals on the surface of each conjugates were
detected directly with 100 mL of commercial CL HRP
substrate.
In the assay without RCA, after the binding of PDGF-BB
onto the surface of wells, 7.5 pmol aptamer–primer complexes
were added to react with the immobilized PDGF-BB. After
the plate was washed three times with PBST (150 mL each
time), 7.5 pmol of biotinylated probe in 100 mL PBS and
1:7500 dilution of SA–HRP were added and captured on the
surface of the wells sequentially (each for 30 min at 37 1C).
Finally, the plate was washed three times with 150 mL of
PBST. The CL signals were also detected as described above.0
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Figure 2 CL intensity vs. the capture antibody amount. Experi-
mental conditions: 5.0 pmol of aptamer–primer, 2.1 pmol of
padlock, 6 U of ligase, 25 U of polymerase, 100 mM of dNTPs,
2.5 pmol of biotinylated probe, 1:5000 dilution of SA–HRP and
10 pM PDGF-BB. The detection procedure was carried out as
described in the Experimental Section 2.4.3. Results and discussion
3.1. Design of the aptamer-based assay
A ‘‘sandwich-type’’ detection strategy was employed with
HRP as the detection tag in our design (Fig. 1), which
involved the sequential immobilization of capture antibody,
PDGF-BB and aptamer–primer onto the 96-well plate surface
in a classic sandwich assay format. The aptamer–primer had
two functional units. The aptamer part was used to recognize
and bind PDGF-BB, and the primer part at the 30-terminus
was employed as a universal primer sequence to initiate a
linear RCA reaction in the presence of Phi 29 polymerase and
dNTPs. Both the 30- and 50-terminus of a padlock probe could
hybridize to the 30-terminus of the aptamer–primer. Ligation
of the padlock probe resulted in a circular template for RCA,
which then produced single-stranded tandem repeated copiesFigure 1 Schematic representation of aptameric system fof the circular template. The tandem repeated copies in the
RCA product were complementary to the biotinylated probe.
Thus, the RCA product could hybridize a number of biotiny-
lated probes, which then captured SA–HRP. After the CL
substrates were added, the CL signal was recorded immedi-
ately with the CL measurement. In contrast, for the assay
without RCA, the biotinylated probes directly hybridized the
aptamer–primer, which had been immobilized on the surface
of the 96-well plate as the formation of antibody–antigen–
aptamer complex, and then SA–HRP reacted with the cap-
tured biotinylated probes. Finally, the CL signal was also
obtained by the reaction with CL substrates and recorded by
the CL measurement. All experiments were performed at least
triplicate.3.2. Optimization of reaction parameters
Several parameters were optimized systematically for the
highly sensitive approach of protein assay, including the
amounts of capture antibody, aptamer–primer, padlock,
ligase, polymerase, dNTPs, biotinylated probe and SA–HRP.or the detection of PDGF-BB with or without RCA.
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Z.-J. Cao et al.1623.2.1. Effect of the capture antibody amount
The amount of capture antibody on the wells played an
important role in the performance of the immunoassay.
Several amounts of anti-PDGF-BB antibody were investigated
as shown in Fig. 2. Elevated CL intensity was observed with
increasing amount of the capture antibody, and peaked at
75 ng of capture antibody. Further increase in the amount of
capture antibody to 100 ng resulted in a decrease of the CL
intensity. This was attributed to steric and electrostatic
hindrances, arising from more tightly packed capture antibody
on the surface of wells, limiting access to the surface-bound
capture antibody by PDGF-BB antigen. Thus, 75 ng capture
antibody was selected for subsequent experiments.5.0x104
1.0x105
CL
 in
te3.2.2. Effects of the amounts of the aptamer–primer and
padlock
The effects of aptamer–primer and padlock amounts were
subsequently examined and optimized. CL intensity increased
in the range of 0.1–7.5 pmol of aptamer–primer and then0
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Figure 3 CL intensity vs. the amounts of aptamer–primer (A)
and padlock (B). Experimental conditions: 75 ng of PDGF-BB
antibody, 6 U of ligase, 25 U of polymerase, 100 mM of dNTPs,
2.5 pmol of biotinylated probe, 1:5000 dilution of SA–HRP and
10 pM PDGF-BB. A, 2.1 pmol of padlock; B, 7.5 pmol of
aptamer–primer. The detection procedure was carried out as
described in the Experimental Section 2.4.decreased slightly (Fig. 3A). CL intensity increased with
increasing amount of padlock sequences over the range of
0.1–5.0 pmol, and then decreased (Fig. 3B). Thus, 7.5 pmol of
aptamer–primer and 5.0 pmol of padlock sequences were
selected in further studies.0
Ligase (U)
15
5.0x104
1.0x105
1.5x105
2.0x105
CL
 in
te
ns
ity
Polymerase (U)
0
8.0x104
1.2x105
1.6x105
2.0x105
CL
 in
te
ns
ity
dNTPs (µM)
2 4 6 8 10
20 25 30 35 40 45
50 100 150 200
Figure 4 CL intensity vs. concentration of RCA reagents.
Experimental conditions: 75 ng of PDGF-BB antibody, 7.5 pmol
of aptamer–primer, 5.0 pmol of padlock, 2.5 pmol of biotinylated
probe, 1:5000 dilution of SA–HRP and 10 pM PDGF-BB. A,
25 U of polymerase, 100 mM of dNTPs; B, 1 U of ligase and
100 mM of dNTPs; C, 1 U of ligase and 40 U of polymerase. The
detection procedure was carried out as described in the Experi-
mental Section 2.4.
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reagents
The amounts of ligase, polymerase and dNTPs also affected
the CL signal in some extent. As shown in Fig. 4, CL intensity
started to increase rapidly as the concentration of ligase
increased from 0 to 1 U, and reached a maximum with 1 U
of ligase. Further increase in the amount of ligase to 10 U
caused a decrease in the CL intensity. Thus, 1 U of ligase was
selected for subsequent experiments. Similarly, 40 U of poly-
merase and 100 mM of dNTPs were selected respectively in
further studies.
3.2.4. Dependence of CL intensity on the amount of report
reagents
The amounts of biotinylated probe and SA–HRP were two
vital factors for the ampliﬁcation of CL signal. Therefore,
these parameters were also investigated. As shown in Fig. 5,
the range of 0.5–10.0 pmol of biotinylated probe and 1:1000 to
1:15 000 dilution of SA–HRP were studied for the optimal
condition. Finally, the maximum CL intensity was obtained
by using 7.5 pmol of biotinylated probe and 1:7500 dilution of0
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Figure 5 CL intensity vs. the concentration of biotinylated probe
and SA–HRP. Experimental conditions: 75 ng of PDGF-BB
antibody, 7.5 pmol of aptamer–primer, 5.0 pmol of padlock,
1 U of ligase, 40 U of polymerase, 100 mM of dNTPs and
10 pM PDGF-BB. A, 1:5000 dilution of SA–HRP; B, 2.5 pmol
of biotinylated probe. The detection procedure was carried out as
described in the Experimental Section 2.4.SA–HRP, which were thus employed for the subsequent
experiments.3.2.5. Analytical performance with or without RCA
Under the above-optimized experimental conditions, the
quantitative behavior of the method was assessed by monitor-
ing the dependence of the CL intensity on the concentration of
the target PDGF-BB. As shown in Fig. 6, a linear relationship
was obtained between the CL intensity and the amount of
PDGF-BB in the range of 10 fM–1 nM (lgI¼0.836 lgCþ0.928,0
1
2
0
lg [PDGF (fM)]
lg
2 4 6 8
Figure 6 Log–log calibration data for PDGF-BB by using the
protocol with RCA (up) and without RCA (down). The detection
procedure was carried out as described in the Experimental
Section 2.4.
Table 2 Comparison of sensitivity for different aptamer-
based assays for PDGF-BB.
Analytical method Label Detection
limit
Fluorescence Cy3 0.4 nM [25]
Fluorescence FAM and
DABCYAL
6.8 pM [26]
Fluorescence Fluorescein 110 pM [42]
Fluorescence TOTO 0.1 nM [44]
Fluorescence SYBR-green 0.1 ng/mL
[45]
Fluorescence Dyes 10 ng/mg [46]
Electrochemical AP 10 fM [27]
Electrochemical Methylene blue 63 pM [28]
Electrochemical Fc 1.0 pg/mL
[43]
Densitometry Gold nanoparticles
(AuNPs)
83 aM [20]
Diffractometric Microbeads 10 pM [23]
Photoluminescence Au-nanodots NPs 10 pM [47]
Colorimetric AuNPs 35 nM [48]
Capillary
Electrophoresis
FAM 50 pM [49]
Luminescence [Ru(phen)2(dppz)]
2þ 1.0 nM [50]
Chemiluminescence HRP 10 fM (this
work)
IgA
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Figure 7 Selectivity of the proposed strategy. Experimental
conditions: 75 ng of PDGF-BB antibody, 7.5 pmol of aptamer–
primer, 5.0 pmol of padlock, 1 U of ligase, 40 U of polymerase,
100 mM of dNTPs, 7.5 pmol of biotinylated probe, 1:7500 dilution
of SA–HRP, 100 pM PDGF-BB and 1 nM of IgA, IgG, IgM and
thrombin. The detection procedure was carried out as described in
the Experimental Section 2.4.
Z.-J. Cao et al.164R2¼0.997, where I is the CL intensity and C is the concentra-
tion of target PDGF-BB). And the detection limit was
estimated at 10 fM. For comparison, the performance of
aptamer-based sandwich assay without RCA was also studied.
A good linear correlation was presented between the CL
intensity and the concentration of PDGF-BB in the range of
10 pM–10 nM (lgI¼0.879 lgC0.446, R2¼0.998). A 1000-fold
enhancement of sensitivity was achieved based on RCA
ampliﬁcation. Thus, it was demonstrated that RCA is power-
ful for signal ampliﬁcation. Furthermore, our CL protocol
allowed detection of PDGF-BB down to fM level and was
competitive with other aptamer-base PDGF-BB assays as
reported previously (Table 2).
3.2.6. Detection speciﬁcity
Sensitivity and speciﬁcity were the two critical factors for a
successful assay system. In the proposed strategy, the sensi-
tivity of our assay compared favorably with previous efforts.
The detection speciﬁcity was also determined and evaluated by
the aptameric recognition function. As shown in Fig. 7,
compared with 100 pM PDGF-BB, the CL intensity from
1 nM of the non-target proteins (IgG, IgA, IgM, interferon
and thrombin) was low. It was demonstrated that the CL
signal was speciﬁcally triggered by the aptamer/target binding.4. Conclusion
A new CL platform for the determination of protein has been
demonstrated by the combination of the aptamer as the
identiﬁcation unit and RCA as the ampliﬁcation unit. This
aptamer-RCA based CL technique has signiﬁcant advantages,
including improved sensitivity and high selectivity. The detec-
tion limit of this novel protocol was demonstrated down to
10 fM, which is a 1000-fold improvement compared to non-
RCA assay, and also comparable to or even better than what
was provided by most previous reports. Furthermore, our
protocol might discriminate the target protein from 10-foldconcentration of other proteins. In summary, this aptamer-
RCA based CL technique possesses great potential to serve as
the PDGF-BB diagnostic tool in clinical test by virtue of its
sensitivity and selectivity. In addition, this new approach can
also be easily extended to the detection of other biomarkers
relating to other diseases, such as IgE or thrombin, etc.Acknowledgments
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